FDA grants fast track status to X4’s neutropenia drug

BOSTON - X4 Pharmaceuticals (NASDAQ:XFOR), a biotech firm focusing on immune system diseases with a market capitalization of $24 million, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug mavorixafor for treating chronic neutropenia (CN). According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a current ratio of 3.7x. The oral medication is currently undergoing a global Phase 3 trial, with full enrollment expected later this year.

The FDA’s Fast Track program aims to expedite the review of drugs that show potential to address unmet medical needs in serious conditions. Mavorixafor, a CXCR4 antagonist, has previously received FDA approval for WHIM syndrome, another rare immunodeficiency, in April 2024. With a gross profit margin of 82%, X4 Pharmaceuticals demonstrates strong operational efficiency in its existing product line. InvestingPro subscribers can access 13 additional key insights about X4’s financial health and market position.

Chronic neutropenia is characterized by low levels of neutrophils, leading to increased infection risks and impacting quality of life. The current standard treatment, injectable granulocyte-colony stimulating factor (G-CSF), approved in the 1990s, can have significant side effects and long-term risks, including leukemia. X4 Pharmaceuticals suggests that mavorixafor may offer a better balance of disease control and treatment burden for patients with certain primary CN conditions.

The ongoing 4WARD trial is evaluating the efficacy, safety, and tolerability of mavorixafor and aims to enroll 150 participants with confirmed low neutrophil counts and a history of infections. The trial’s primary endpoint includes annualized infection rate and positive neutrophil count response.

X4 Pharmaceuticals, based in Boston, Massachusetts, is leveraging its expertise in CXCR4 biology to develop therapies for rare immune diseases. The company markets mavorixafor under the brand XOLREMDI® in the U.S. and continues to explore its potential in other indications.

The information presented in this article is based on a press release statement from X4 Pharmaceuticals. While analysts project 13% revenue growth for fiscal year 2025, InvestingPro’s comprehensive analysis indicates the company is currently fairly valued. Discover detailed valuation metrics and growth projections in the exclusive Pro Research Report, available for over 1,400 US stocks.

In other recent news, X4 Pharmaceuticals reported a notable earnings beat for the first quarter of 2025, with an earnings per share (EPS) of $0.04, surpassing the forecasted loss of $0.12. Revenue also exceeded expectations, reaching $28.81 million, significantly higher than the anticipated $12.03 million. The strong financial results were largely attributed to the company’s partnership with Norgene and strategic cost management initiatives. Following these developments, H.C. Wainwright raised its price target for X4 Pharmaceuticals to $7.00 from $1.50, maintaining a Buy rating on the stock. X4 Pharmaceuticals is advancing its Phase 3 4WARD study, focusing on mavorixafor for chronic neutropenia, with plans to complete enrollment by the second half of 2025 and release topline data in the second half of 2026. The company also implemented a reverse stock split to address NASDAQ listing requirements. Additionally, X4 Pharmaceuticals is working towards expanding its market reach, aiming for EMA approval for the WHIM indication by the first quarter of 2026. The company’s strategic restructuring is projected to reduce annual spending by $30-35 million, supporting operations into the first half of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.